Author | Michael R. Harrison, MD | OncLive

Author | Michael R. Harrison, MD

Articles

Dr. Harrison on Choosing Frontline Treatment for RCC

December 01, 2017

Video

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).

Dr. Harrison on the Possibility of Nivolumab Plus Ipilimumab Becoming the New IL-2

October 20, 2017

Video

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses the possibility of nivolumab (Opdivo) plus ipilimumab (Yervoy) becoming the new interleukin-2 (IL-2).

x